Posted on November 4, 2016 by Sitemaster
A recent review article in the journal Nature Reviews: Urology has concluded that, while we are learning a lot more about the potential role(s) of statins in the prevention and management of prostate cancer, we still have no definitive evidence of their value. … READ MORE …
Filed under: Management, Prevention, Risk, Treatment | Tagged: delay, Prevention, progression, risk, statin | 3 Comments »
Posted on March 7, 2016 by Sitemaster
Patients are often concerned about delaying initiation of treatment. Will it give the cancer a chance to metastasize? What if the random biopsy didn’t detect existing higher grade cancer? This is particularly of concern to patients considering active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: delay, Diagnosis, initiation, outcome, radiation, risk, Treatment | 2 Comments »
Posted on October 24, 2014 by Sitemaster
On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: delay, radium-223, shortage, Xofigo | 3 Comments »
Posted on March 10, 2014 by Sitemaster
Daily treatment with sildenafil citrate (Viagra) seems to have been able to help maintain erectile function for up to 2 years among men receiving such adjuvant treatment during and after radiotherapy for localized prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: delay, dysfunction, erectile, Prevention, radiotherapy, sildenafil, Viagra | 1 Comment »
Posted on July 30, 2012 by Sitemaster
A paper published in June this year in the Journal of Sexual Medicine suggests that delaying radical prostatectomy (RP) as a first-line treatment for localized prostate cancer has no significant effects on post-surgical pathology or mortality but may lead to higher risk for incontinence and erectile dysfunction. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: delay, outcome, quality, radical prostatectomy, RP, side effects, surgery | Leave a comment »
Posted on August 24, 2011 by Sitemaster
As a mentioned earlier this week, a new article by Moyad and Klotz has suggested that it may be possible to carry out a randomized clinical trial to evaluate the impact of statin therapy on the progression of early stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cholesterol, delay, progression, red yeast rice, RYR, statin | 2 Comments »
Posted on May 22, 2011 by Sitemaster
A presentation at the American Urological Association annual meeting in Washington a few days ago provided data that treatment with denosumab (Xgeva) delayed the onset of bone metastasis by 4.2 months compared to treatment with a placebo in men with high-risk, non-metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: bone, delay, denosumab, metastasis, survival | Leave a comment »
Posted on April 20, 2011 by Sitemaster
For any man with a first-time PSA level > 10 ng/ml, there is significant risk for prostate cancer, and early follow-up care — including a repeat PSA test and potentially a biopsy — is probably a priority unless the patient has a life expectancy of 10 years or less. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: care, delay, Diagnosis, follow-up, work-up | Leave a comment »
Posted on December 14, 2010 by Sitemaster
According to a media release, issued late yesterday by Amgen, treatment with denosumab can significantly improve bone metastasis-free survival compared to treatment with a placebo in men with castrate-resistant prostate cancer (CRPC), a rising PSA, but no evidence of bone metastases. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: delay, denosumab, metastasis, outcome, Prevention, survival | Leave a comment »